Is BTAI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BTAI. It does not provide personalized investment advice.

BTAI (BioXcel Therapeutics, Inc. Common Stock) Stock Analysis - Financials

BioXcel Therapeutics, Inc. Common Stock (BTAI) is a publicly traded Healthcare sector company. As of August 3, 2026, BTAI trades at $0.82 with a market cap of $24.95M and a P/E ratio of -0.18. BTAI moved +0.00% today. Year to date, BTAI is -47.19%; over the trailing twelve months it is -38.32%. Its 52-week range spans $0.74 to $9.26. Rallies surfaces BTAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are BTAI's key financials?

BTAI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BTAI recently traded at $0.82. Market cap is $24.95M. P/E ratio is -0.18. Revenue is $680.00K.

BTAI Key Metrics

Key financial metrics for BTAI
Metric	Value
Price	$0.82
Market Cap	$24.95M
P/E Ratio	-0.18
EPS	$-4.52
Dividend Yield	0.00%
52-Week High	$9.26
52-Week Low	$0.74
Volume	111.17K
Avg Volume	0
Revenue (TTM)	$680.00K
Net Income	$-75.33M
Gross Margin	36.32%

BTAI Analyst Consensus

BTAI analyst coverage data. Average price target: $0.00.

Common questions about BTAI

What are BTAI's key financials?: BTAI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BTAI recently traded at $0.82. Market cap is $24.95M. P/E ratio is -0.18. Revenue is $680.00K.
Is BTAI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BTAI. It does not provide personalized investment advice.